January 28, 2025

FDA Approves Enhertu for Metastatic, HR-Positive, HER2-Low or -Ultralow Breast Cancer

Enhertu, a HER2-directed antibody-drug conjugate, was approved by the U.S. Food and Drug Administration for pretreated patients with metastatic HR-positive, HER2-low or HER2-ultralow breast cancer based on results from the DESTINY-Breast06 trial.

Conexiant

January 28, 2025

Medicare Study Compares LVRS, EBV Outcomes

"Medicare beneficiaries who undergo EBV present with fewer comorbidities, but after risk adjustment they have higher mortality and procedure-related morbidity than those undergoing LVRS," finds study of 3,219 patients comparing contemporary surgical outcomes.

Conexiant

January 28, 2025

Surgeon Preference Reframes CABG Arterial Grafting Outcomes

Medicare analysis of 1M+ CABG procedures challenges conventional wisdom on multi-arterial grafting survival benefits when accounting for surgeon preference patterns.

Conexiant

January 27, 2025

Long-term Mortality Decreases With Mechanical AVRs Under 60

"With national clinical evidence from over 100,000 patients...the signal of the survival benefit of mechanical valves starts at age 65 but is most clear at age 60 or younger," challenging current trends toward bioprosthetic valves in younger patients.

Conexiant

January 27, 2025

Ross Procedure Shows 90% Survival at 20 Years

"Freedom from re-intervention was 91% at 10 years and 87% at 20 years," reports long-term study of 252 patients who underwent Ross procedure for aortic valve disease.

Conexiant

May 01, 2024

ACC 2024: Does Long-Term Use of ADHD-Related Stimulants Raise the Risk of Cardiomyopathy?

Investigators detailed the potential risk of cardiomyopathy in young adult patients with attention-deficit/hyperactivity disorder (ADHD) who were treated with stimulants.

Conexiant

May 02, 2024

AACR 2024: Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.

Conexiant

May 15, 2024

ACC 2024: Can an App Improve Access to Nonprescription Statins?

A novel web-based application designed to qualify patients with high low-density lipoprotein (LDL) cholesterol for treatment with nonprescription statins may be comparable to physician assessment.

Conexiant

May 22, 2024

DDW: Adjuvant Therapy May Improve Rectal Adenocarcinoma Survival

Adjuvant therapy may be underutilized in patients with clinical T2N0 rectal adenocarcinoma, according to new findings presented at Digestive Disease Week 2024.

Conexiant